文献速递皮肤肿瘤

病灶内白细胞介素2治疗皮肤鳞状细胞癌

Intralesional Interleukin-2 Therapy for Treatment of Cutaneous Squamous Cell Carcinoma.
PubMed 文献 · JAMA Dermatol · 2026-01-01

这项病例系列研究在2017至2024年间纳入16例组织学确诊的皮肤鳞状细胞癌患者,均因既往手术失败、合并症不适合手术或位于美容敏感部位而接受病灶内IL-2治疗。结果显示完全缓解率为81%(13例),无进展生存期为19个月,仅观察到1/2级不良事件。作者认为病灶内IL-2可作为高合并症或美容敏感部位患者的治疗选择,但需随机试验进一步验证。

要点

  • 病灶内IL-2在皮肤鳞状细胞癌中完全缓解率达81%(13/16)。
  • 仅观察到1/2级不良事件,安全性良好。
  • 无进展生存期为19个月,治疗次数中位10次(范围2-32)。

核心结论

  • 病灶内IL-2治疗皮肤鳞状细胞癌有效,完全缓解率为81%(13例),无进展生存期为19个月。
  • 仅观察到1/2级不良事件,安全性良好。
  • 作者建议对高合并症或美容敏感部位患者可考虑病灶内IL-2,但需随机试验验证。

研究设计与样本

  • 单中心病例系列研究,2017至2024年纳入16例组织学确诊的皮肤鳞状细胞癌患者。
  • 患者因既往手术失败、合并症不适合手术或位于美容敏感部位而接受病灶内IL-2治疗。
  • 病灶内IL-2每两周注射一次,浓度0.1 mL/2 mm²(500 000 IU/0.1 mL),按免疫相关疗效评价标准评估反应。

主要发现

  • 16例患者平均年龄79岁(范围59-99岁),男性9例(56%)。
  • 平均治疗次数10次(范围2-32),平均治疗持续时间13个月(范围2-32)。
  • 无进展生存期19个月(范围1-77个月),完全缓解率81%(13例)。
  • 仅观察到1/2级不良事件。

关键数值与推荐

  • 完全缓解率81%(13/16),无进展生存期19个月(范围1-77个月)。
  • 注射方案为0.1 mL/2 mm²(500 000 IU/0.1 mL),每两周一次。
  • 疗效评估采用免疫相关疗效评价标准(irRECIST)。

临床怎么用

  • 对因合并症不适合手术或位于美容敏感部位的皮肤鳞状细胞癌患者,可考虑病灶内IL-2治疗。
  • 治疗期间需按irRECIST评估反应,持续注射至出现疾病进展证据。
  • 相比系统性免疫治疗成本较低且操作简便,可在成本受限环境中作为选择。

局限性

  • 本研究为单中心病例系列,样本量小(16例),无对照组。
  • 作者指出需要随机试验来充分阐明这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cutaneous squamous cell carcinoma (cSCC) remains one of the most common cancers affecting the general population. It is generally cleared surgically, yet it is challenging to manage recurrent disease, locally advanced disease, or disease in anatomically sensitive areas among patients, with few options available. OBJECTIVE: To assess whether intralesional interleukin 2 (iIL-2) can effectively treat patients with high-risk or cosmetically sensitive cSCC. DESIGN, SETTING, AND PARTICIPANTS: This case series took place at a single high-volume referral center for surgical oncology and intralesional immunotherapy for melanoma between 2017 and 2024. The center had considerable experience treating patients with locoregionally advanced melanoma using iIL-2, with high clinical efficacy and low treatment-related toxic effects. Patients referred to the immunotherapy program had histologically confirmed cSCC and failed prior surgical attempts or comorbidities that made them not candidates for surgery. Additionally, some patients had cSCC in cosmetically sensitive sites and were referred for a trial of intralesional immunotherapy prior to surgery. EXPOSURE: Intralesional IL-2 was administered biweekly at a concentration of 0.1 mL/2 mm2 to clinically positive lesions (500 000 IU/0.1 mL), and responses were recorded according to Immune Response Evaluation Criteria in Solid Tumors criteria. Injections were continued while patients responded and were stopped if any evidence of disease progression occurred. MAIN OUTCOMES AND MEASURES: The main outcome was progression-free survival, defined as time from last follow-up or progression for the cohort. Adverse events were also observed. RESULTS: Among 16 patients with cSCC (mean [range] age, 79 [59-99] years; 9 [56%] male) who received iIL-2, the mean (range) number of treatments was 10 (2-32) and treatment duration was 13 (2-32) months. Progression-free survival was 19 months (range, 1-77 months), with a complete response rate of 81% (13 patients). Only grade 1/2 adverse events were observed. CONCLUSIONS AND RELEVANCE: In this case series, IL-2-based immunotherapy was effective in the treatment of cSCC. With the degree of complete response observed, iIL-2 should be considered an option for patients with considerable comorbidities or with cSCC in highly sensitive areas. Additionally, given its low cost compared to systemic immunotherapy and ease of use, iIL-2 represents an option in cost-prohibitive settings. Further randomized trials are required to fully elucidate these findings.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Giacomantonio CA, Vidovic D, Cruickshank B, et al. Intralesional Interleukin-2 Therapy for Treatment of Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2026. PMID: 41848721. doi:10.1001/jamadermatol.2026.0181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。